title: Reduction of DNA synthesis, pigment synthesis, pigmentation gene mRNA and resistance to UVB in human melanoma cells treated with analogues of a histamine (H2) agonist.
abstract: Two groups of S-[2-(N,N-dialkylamino)ethyl]isothiourea derivates which depigmented melanoma cells either with inhibition of tyrosinase (group 1, R = methyl, isopropyl) or without inhibition of tyrosinase (group 2, R = benzyl, phenyl) were studied. Treatment of human melanoma cells with non-lethal doses of group 1 drugs led to a reduction in the levels of mRNA for the pigmentation genes tyrosinase, tyrosinase-related protein-1 and Pmel 17. The group 1 drug S-[2-N,N-diisopropylamino)ethyl[isothiourea] (DINOR) (R = isopropyl) produced only moderate inhibition of DNA, RNA and protein synthesis in three cell lines during the first 24 hr of treatment, and there was no correlation between the extent of inhibition and long-term toxicity. A group 2 drug (R = benzyl) rapidly inhibited DNA synthesis in an amelanotic melanoma cell line (MM96E) sensitive to killing by the drug; association of the latter with inhibition of RNA or protein synthesis was less clear. MM96E cells were also sensitive to killing by reactive oxygen species. In pigmented melanoma cells (MM418), incorporation of [125I]thiouracil, a false precursor of melanin, increased during the first 24 hr of treatment with DINOR whereas a group 2 drug (R = phenyl) inhibited incorporation of [125I]thiouracil. Cells depigmented by treatment with drugs from either group suffered the same amount of DNA damage as pigmented cells after UVB irradiation, as judged by inhibition of DNA synthesis, but did not recover as well as pigmented cells, whether or not drug was present during recovery. The results suggested that (1) group 1 agents down-regulated message for several pigmentation genes, possibly at the transcriptional level; (2) the toxicity of group 2 drugs was related to reactive oxygen species; and (3) melanin protected cells from UVB by enhancing cellular recovery.
authors.affiliation: Pharmacy Department, University of Queensland, Australia.
authors.forename: G A
authors.initials: GA
authors.lastname: Fechner
authors.forename: J
authors.initials: J
authors.lastname: Michel
authors.forename: R A
authors.initials: RA
authors.lastname: Sturm
authors.forename: J J
authors.initials: JJ
authors.lastname: Jacobs
authors.forename: P G
authors.initials: PG
authors.lastname: Parsons
mesh_terms: D015152:Blotting, Northern; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D004273:DNA, Neoplasm / Q000096:biosynthesis*; D017259:Dimaprit / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D017442:Histamine Agonists / Q000494:pharmacology*; D006801:Humans; D007550:Isothiuronium / Q000737:chemistry / Q000494:pharmacology; D008543:Melanins / Q000096:biosynthesis* / Q000235:genetics; D008545:Melanoma; D014442:Monophenol Monooxygenase / Q000037:antagonists & inhibitors / Q000378:metabolism; D010858:Pigmentation / Q000235:genetics*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000378:metabolism*; D012334:RNA, Neoplasm / Q000096:biosynthesis / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014466:Ultraviolet Rays
chemical_list: D004273:DNA, Neoplasm; D017442:Histamine Agonists; D008543:Melanins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C025838:nordimaprit; D007550:Isothiuronium; D014442:Monophenol Monooxygenase; D017259:Dimaprit